Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Estee Lauder

International Flavors & Fragrances

Retail is a dynamic world, and the winds of change are ever-present. The sector has historically been a barometer of economic health and consumer confidence.

3 Sorry Retail Stocks to Sell in August Before It's Too Late

Stanley Black & Decker

AT&T

Value traps are stocks that appear cheap based on valuation multiples but may actually be fully valued or expensive when considering enterprise valuation and the cash-based sources of intrinsic value. Valuation multiples can be misleading, and the balance sheet is a critical component of value that is often ignored. Many value traps have low valuation multiples due to large net debt positions, making a low P/E more often indicative of a potential value trap rather than an undervalued stock.

3 Potentially Dangerous Value Traps

Bank of Nova Scotia

Crown Castle International

Citizens Financial Group

Comerica

Columbia Banking System

Dow Inc

Fifth Third Bancorp

Foot Locker

International Paper

KeyCorp

Kohl's

Leggett & Platt

PNC Financial Services

Prudential Financial

Simon Property Group

Suncor Energy

Truist Financial

TC Energy

Bonds will do well if U.S. interest rates decline in coming months. What you may not appreciate is that dividend-paying stocks are likely to do even better.

These 20 dividend-paying stocks get a double boost from declining interest rates

Boeing

Disney

Blue-chip stocks are considered a more conservative way to invest, relative to more speculative names like early-stage growth stocks or penny stocks. However, that doesn't mean owning them offers a guaranteed path to solid returns.

7 Sorry Blue-Chip Stocks to Sell in August Before It's Too Late

American Electric Power Company

EPR Properties

Energy Transfer LP Unit

Altria

Southern Company

Verizon

The writing could be on the wall, as the Moody's downgrade was poo-pooed by many across Wall Street as “late to the party.

Sell Any August Rally as September May Be a Disaster: 7 Safe-Haven Dividend Buys

PayPal

QUALCOMM

After the stock market's dismal performance in 2022, investors are savoring this year's rally. The Nasdaq Composite Index surged 33% higher in the first half of the year, though the growth-oriented index seems to have stalled out since.

3 Beaten-Down Value Stocks You'll Regret Not Buying During This Nasdaq Correction

CVS Health

This is an update to an earlier article I published on Walgreens and CVS back in April 2023. That article evaluated Walgreens and CVS using Peter Lynch's approach for dividend stocks, and the results showed WBA to be the more attractive dividend stock back then. This update is triggered by the new financial information and they both released new earnings reports since that write-up.

Walgreens Vs. CVS: I Call A Tie Now Based On A Peter Lynch Evaluation

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is offering in-store vouchers and off-site vaccination clinics through its employer vaccination program, and is rolling out a low-cost, 2 results in 1 test for flu and COVID-19 this fall respiratory virus season. These new services support insights gleaned from a recent consumer survey commissioned by Walgreens that reveals many prefer going to local pharmacies because of their ease and convenience.1 Key findings from a survey of more than 1,000 adult.

Walgreens Announces New Vaccination and Testing Offerings Ahead of Fall Respiratory Virus Season

Walgreens has been selling billions of dollars worth of AmerisourceBergen stock over the past year. The pharmacy retailer's business isn't generating enough operating cash flow to pay down debt, fund growth, and pay dividends.

Is This a Sign Walgreens Boots Alliance Is Getting Desperate?

Walgreens (WBA) and VillageMD's coordinated primary care and pharmacy services are now available in Chicago.

Walgreens (WBA) and VillageMD Expand Partnership in Chicago

A federal appeals court on Tuesday revived a lawsuit by the United States and Virginia that accused Walgreens Boots Alliance of misrepresenting that some patients met Virginia's Medicaid-eligibility requirements for expensive hepatitis C drugs.

Walgreen must face US lawsuit alleging false claims over hepatitis C drugs

Agree Realty

Essential Properties Realty Trust Inc

National Retail Properties

Realty Income Corp

iStar Inc

Uniti Group

Vanguard Real Estate ETF

Walmart

REITs are currently undervalued. And insiders are buying millions worth of shares. I highlight three REITs with significant insider purchases.

Insider Buys: 3 REITs With $1+ Million Investments

Amazon

Nurse practitioners – not doctors – topped AMN Healthcare's list of “most requested search engagements for the third consecutive year."

Doctor, Nurse Practitioner Pay Rising As Amazon, CVS And Walgreens Buy Providers

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Chevron

Essex Property Trust

Federal Realty Investment Trust

Medtronic

NextEra Energy

Sysco

Target

T. Rowe Price Group

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. " - Kiplinger.com/Investing. 66 Aristocrats, screened as of August 9, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net gains ranged 15.54%-31.28% topped by TGT and NEE. By yield, WBA topped-all Aristocrats. Top-ten Yields from ESS, ABBV, FRT, BEN, TROW, IBM, AMCR, O, MMM, & WBA, averaged 4.78%.

3 Dividend Aristocrat Buys For August And 6 To Watch

Amgen

Salesforce

Cisco Systems

Goldman Sachs

Honeywell

Intel

JPMorgan Chase & Co

Coca-Cola

Merck

Microsoft

NIKE

Travelers

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are August's Dogs of the Dow: CSCO, KO, GS, AMGN, CVX, IBM, DOW, MMM, WBA, and VZ, averaged a 4.63% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated August net-gains ranged 15.75%-33.3%, topped by VZ 8/4/23.

Buy 2 August Dogs Of The Dow, Watch 5

News for Walgreens Stock (WBA)